Thursday, September 15, 2016
BESTie Chelsea Gregg has been selected for the prestigious American Institute for Medical and Biological Engineering (AIMBE) award for post-doctoral scholars to combine regulatory and policy expertise at the US Food and Drug Administration (FDA).
AIMBE is an honorific society of the top 2% of medical and biological engineers responsible for medical discovery and innovation. For more details please visit aimbe.org/scholars-program.
Excerpts from the Press Release (to read it in full, see the link below):
AIMBE Partners with FDA for 2016-2017 Scholars Program
American Institute for Medical and Biological Engineering (AIMBE) announces the 2016-2017 Scholars selected for participation in 9-month and one-year appointments with the U.S. Food and Drug Administration (FDA). AIMBE has partnered with the FDA to offer regulatory science and policy appointments to post doctoral scholars with advanced training in medical and biological engineering. Scholars work side-by-side with influential decision makers in the Center for Devices and Radiological Health at the agency The AIMBE Scholars Program infuses the FDA with the latest innovative science tools and techniques that medical and biological engineering have to offer. The 2016-2017 AIMBE Scholars placed at FDA include Brittany Caldwell, Ph.D., Christine Cezar, Ph.D., and Chelsea L. Gregg, Ph.D. Their appointments at the agency begin on October 1.
The AIMBE Scholars Program enables distinguished postdoctorates in the medical and biomedical engineering fields to serve as expert advisors to policy makers at the FDA. Scholars learn how to apply their experiences from the lab bench to inform regulatory policy decisions. Scholars receive training about regulatory science and policy and build relationships with key government stakeholders. In turn, Scholars share their knowledge of the latest cutting-edge research and technological innovations with the FDA. They extend the capacity of the FDA and work toward streamlining regulatory processes at the agency through a variety of projects. They may be involved in standards development and the development of metrics to evaluate and inform agency programs and decision-making. The AIMBE Scholars Program is made possible with generous support from Medtronic, St. Jude Medical Foundation, BD, and C.R. Bard. Each of these companies is represented in AIMBE’s Industry Council and works to advance medical and biological engineering innovation.
Chelsea L. Gregg, Ph.D. Dr. Gregg is an AIMBE Scholar at the U.S. Food and Drug Administration in the Center for Devices and Radiological Health. She completed her Ph.D. in biomedical engineering at Cornell University with minors in applied/engineering physics and developmental biology. Dr. Gregg’s research focused on the development of new and adaptation of current imaging approaches for 3D quantitative analysis of live embryonic morphogenesis using micro-computed tomography. During her tenure at Cornell, Dr. Gregg served as the Vice-President, President, and Past President Advisor of the Biomedical Engineering Society student chapter where she focused on the development and implementation of youth science and engineering outreach efforts. Dr. Gregg founded the Advancing Science and Policy (ASAP) organization, a student-run effort that fosters student involvement in science policy. As President of ASAP, she led semi-monthly roundtable discussions about science policy topics, facilitated science communication efforts, and organized yearly trips to Washington, DC to engage with Congress. As an AIMBE Scholar, Dr. Gregg is excited to be at the forefront of the latest innovative medical technologies and regulatory science. Her goal is to advise in the regulatory needs and strengthen communication between the FDA, industry, and general public for translating novel medical technologies safely into the clinic.
|See http://aimbe.org/press/2016-2017_Scholars_Press_Release.pdf for more information.|